Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 132

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 132
---
 existing balances of cash and cash equivalents will be insufficient to satisfy our working capital needs and other liquidity
requirements associated with our existing operations over the next 12 months.

Our
future viability is dependent on our ability to raise cash from financing activities to finance our development plans until milestone
and/or royalties can be secured from partnering our assets. Our failure to raise capital as and when needed could have a negative impact
on its financial condition and ability to pursue its business strategies.

We
believe there are adequate options and time available to secure additional financing for the Company, including the Committed Equity Financing,
and after considering the uncertainties, we consider it is appropriate to continue to adopt the going concern basis in preparing the financial
information. Our consolidated financial information have therefore been presented on a going concern basis, which contemplates the realization
of assets and the satisfaction of liabilities in the normal course of business. With respect to the Committed Equity Financing, we may
ultimately decide to sell to the Selling Shareholder all, some or none of the Depositary Shares that may be available for us to sell to
the Selling Shareholder pursuant to the Purchase Agreement. Accordingly, we cannot guarantee that we will be able to sell all of the Commitment
Amount or how much in proceeds we may obtain under the Purchase Agreement. If we cannot sell securities under the Committed Equity Financing,
we may be required to utilize more costly and time-consuming means of accessing the capital markets, which could have a material adverse
effect on our liquidity and cash position.

The
consolidated interim financial information has been presented on a going concern basis, which contemplates the realization of assets and
the satisfaction of liabilities in the normal course of business.

As
at June 30, 2024, we had cash and cash equivalents of £5.06 million. We forecast we currently has enough cash to fund its planned
operations into the first quarter of 2025. If we do not secure additional funding before the first quarter of 2025, we will no longer
be a going concern and would likely be placed in Administration.

We
have prepared cash flow forecasts and considered the cash flow requirement for the Group for the next three years including the period
12 months from the date of approval of this interim financial information. These forecasts show that further financing will be required
before the first quarter of 2025 assuming, inter alia, that certain development programs and other operating activities continue as currently
planned. If we raise additional funds through the issuance of debt